Hycanthone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hycanthone
Hycanthone.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.019.512
Chemical and physical data
Formula C20H24N2O2S
Molar mass 356.48 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Hycanthone is the schistosomicide approved by the FDA in 1975. It is a metabolite of lucanthone. Hycanthone interferes with parasite nerve function, resulting in paralysis and death. This agent also intercalates into DNA and inhibits RNA synthesis in vitro and shows potential antineoplastic activity.[1]

Anti-schistosomal activity[edit]

Hycanthone is shown to be an effective inhibitor of acetylcholinesterase (AChE) from Schistosoma mansoni, but is less potential against AChE from mammalian origin. This might come from differences in the configuration of active center between schistosome and mammalian AChE enzymes..[2]

Hycanthone is shown to intercalates into DNA and inhibit RNA synthesis in vitro. A growing body of evidence has shown that hycathone has an antineoplastic activity.

Clinical trials[edit]

  • Phase II Study of Chemotherapy with Hycanthone for Advanced Colorectal Carcinoma (Completed)
  • Phase II Chemotherapy with Hycanthone Mesylate and Flagyl for Advanced Malignant Lymphomas (Completed)[3]

Physical properties[edit]

Physical state Solid
Solubility Soluble in ethanol, methanol, DMSO, and water
Absorption maximum 233, 258, 329, 438 nm
Melting point 173-176 °C
logP 3.74

References[edit]

  1. ^ NCI Cancer Dictionary
  2. ^ Hillman, GR; Senft, AW (1975). "Anticholinergic properties of the antischistosomal drug hycanthone". The American journal of tropical medicine and hygiene. 24 (5): 827–834. PMID 1190369. 
  3. ^ http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=10235377